Results 11 to 20 of about 2,325 (161)
Extracellular Vesicle‐Mediated Nucleolin Transfer in Glioblastoma: A Targetable Axis Driving Blood‐Tumour Barrier Formation [PDF]
Journal of Extracellular VesiclesGlioblastoma (GBM) remains a significant therapeutic challenge. While GBM‐derived extracellular vesicles (EVs) are known to remodel the normal blood‐brain barrier (BBB) into a blood‐tumour barrier (BTB), the underlying mechanism is largely not understood.
Hongzhen Chen +7 more
doaj +3 more sources
AS1411-Bivalent-Cholesterol-Anchor Equipped with Zinc Phthalocya-Nine Enables NK Cells Derived Exosomes to Realize Effective Tumor-Tropism Photodynamic Therapy [PDF]
PharmaceuticsBackground/Objectives: Benefiting from their outstanding tumor-penetrating ability and cytotoxic proteins and cytokines, natural-killer-cell-derived exosomes (NEX) show great potential for cell-free tumor immunotherapy.
Yuchen Qi +7 more
doaj +2 more sources
Synthesis and Evaluation of AS1411-Lenalidomide-Targeted Degradation Chimera in Antitumor Therapy [PDF]
PharmaceuticalsBackground: High expression of nucleolin (NCL) on the surface of tumor cells is closely associated with disease progression and poor prognosis. The aptamer–PROTAC conjugate (APC) technology provides a novel molecular design strategy for the targeted ...
Xueling Ma +11 more
doaj +2 more sources
The G-quadruplex-forming aptamer AS1411 potently inhibits HIV-1 attachment to the host cell. [PDF]
Int J Antimicrob Agents, 2016 AS1411 is a G-rich aptamer that forms a stable G-quadruplex structure and displays antineoplastic properties both in vitro and in vivo. This oligonucleotide has undergone phase 2 clinical trials. The major molecular target of AS1411 is nucleolin (NCL), a multifunctional nucleolar protein also present in the cell membrane where it selectively mediates ...
Perrone R +6 more
europepmc +3 more sources
Pharmaceutics, 2021 The nucleolin-binding G-quadruplex AS1411 aptamer has been widely used for cancer therapy and diagnosis and linked to nanoparticles for its selective targeting activity.
Giulia Vindigni +6 more
doaj +1 more source
Molecular Therapy: Nucleic Acids, 2022 Immune-checkpoint blockade (ICB) therapy has changed the clinical outcome of many types of aggressive tumors, but there still remain many cancer patients that do not respond to these treatments.
Daniel Meraviglia-Crivelli +6 more
doaj +1 more source
Aptamer-modified carbon dots for enhancement of photodynamic therapy of cancer cells
Talanta Open, 2022 Carbon dots (CDs) have emerged as promising materials for photodynamic therapy (PDT) because of their intriguing photochemical properties, high stability, and low toxicity.
Menghui Ma +6 more
doaj +1 more source
Anti-Proliferative Effect of Doxorubicin-Loaded AS1411 Aptamer on Colorectal Cancer Cell [PDF]
Asian Pacific Journal of Cancer Prevention, 2021 Doxorubicin (Dox) inhibits DNA replication and causes DNA damage resulting in cell death. It is a common drug for treatment of many cancers. Treatment efficacy and side effects of Dox are critical issues in using it because the drug lacks of specificity. The objective of this study was to improve the specificity of Dox by the incorporation of this drug
Lohlamoh, Walaiporn +2 more
openaire +2 more sources
Frontiers in Pharmacology, 2023 Multifunctional nanocarrier platforms have shown great potential for the diagnosis and treatment of liver cancer. Here, a novel nucleolin-responsive nanoparticle platform was constructed for the concurrent detection of nucleolin and treatment of liver ...
Liangliang Xiang +6 more
doaj +1 more source
A Synthetic Aptamer-Drug Adduct for Targeted Liver Cancer Therapy. [PDF]
PLoS ONE, 2015 AS1411 (previously known as AGRO100) is a 26 nucleotide guanine-rich DNA aptamer which forms a guanine quadruplex structure. AS1411 has shown promising utility as a treatment for cancers in Phase I and Phase II clinical trials without causing major side ...
Thu Le Trinh +7 more
doaj +1 more source